| Literature DB >> 33869730 |
Mohammad Sadeq Mottaqi1, Fatemeh Mohammadipanah1, Hedieh Sajedi2.
Abstract
PROBLEM: The lately emerged SARS-CoV-2 infection, which has put the whole world in an aberrant demanding situation, has generated an urgent need for developing effective responses through artificial intelligence (AI). AIM: This paper aims to overview the recent applications of machine learning techniques contributing to prevention, diagnosis, monitoring, and treatment of coronavirus disease (SARS-CoV-2).Entities:
Keywords: Artificial intelligence; COVID-19; Coronavirus; Deep learning; Machine learning; Respiratory infection; SARS-CoV-2
Year: 2021 PMID: 33869730 PMCID: PMC8044633 DOI: 10.1016/j.imu.2021.100526
Source DB: PubMed Journal: Inform Med Unlocked ISSN: 2352-9148
An overview of applied novel AI models to prevent SARS-CoV-2 infection.
| Method | Type | Purpose of analysis | Performance | Reference |
|---|---|---|---|---|
| CNN | DL | Identifying SARS-CoV-2 coughs from other kinds of coughs | 96% sensitivity and 95% specificity | [ |
| Cloning, Codon optimization, and Immune simulation | In-silico | Developing a stable multi-epitope vaccine | World population coverage of 95.78% for selected epitopes | [ |
| Molecular docking | Immune-informatics analysis | Identifying suitable recognizable epitopes | Model “Z” score of −3.82 using ProSA server | [ |
| Vaxign-ML | ML | Predicting SARS-CoV-2 vaccine candidates | Five supervised ML classification algorithms were employed | [ |
An overview of applied novel AI models in the field of diagnosis of the SARS-CoV-2 infection.
| Method | Type | Purpose of analysis | Performance | Reference |
|---|---|---|---|---|
| ANN, RF, and Shallow learning | ML and DL | Identifying SARS-CoV-2 patients merely based on full blood counts | AUC of 86% | [ |
| CNN, SVM, RF, and MLP | ML and DL | Identifying SARS-CoV-2 patients through chest CT images analysis | AUC of 92%, and sensitivity same as a senior radiologist | [ |
| CNN | DL | Identifying SARS-CoV-2 patients through chest CT images analysis | AUC of 97.7%, sensitivity of 90%, and specificity of 96% | [ |
| COVNet | DL | Detecting SARS-CoV-2 infection using CT images | AUC of 96%, sensitivity of 90%, and specificity of 96% | [ |
| Combination of DL algorithms | DL | Classifying the SARS-CoV-2 patients by CT images | Accuracy of 90.8%, sensitivity of 84%, and specificity of 93% | [ |
| "VB.Net" Neural Network | DL | Segmenting and quantifying the SARS-CoV-2 infected lung areas by CT images | Dice similarity coefficients of 0.916 | [ |
| CovidGAN | DL | Producing synthetic CXR images to boost CNN performance in the detection of the infection | CNN classification accuracy increased to 95% | [ |
| VGG16 | DL | Identifying SARS-CoV-2 patients by CXR images | F-measure of 95–99% | [ |
| ISI, LSTM, and NLP | DL | Predicting the infection rate of the SARS-CoV-2 virus | ISI + NLP + LSTM achieved a more precise prediction than any other models | [ |
| SVR | ML | Predicting the number of positive cases, active cases, recoveries, and freshly found cases in US | More than 92% overall | [ |
| RS-SVM, Bayesian Ridge, and | ML | Forecasting the number of positive cases | Accuracy of 85% | [ |
| RNN | DL | Predicting the recovery and mortality rate for each country | Accuracy of 89% | [ |
| ES, LR, and LASSO | Regression analysis | Estimating the number of freshly positive cases, deaths, and recoveries over the next ten days | ES model achieved higher performance | [ |
| PA | Forecasting analysis | Estimating the number of new positive cases, deaths, and recoveries over the next seven days | Accuracy of 95% and 88% in Australia and Jordan, respectively | [ |
| SVM, NB, DT, RF, and LR | ML | Forecasting the recovery chance of infected patients | DT achieved an accuracy of 99.85% | [ |
An overview of the employed novel AI models in the field of monitoring the SARS-CoV-2. Not specified.
| Method | Type | Purpose of analysis | Performance | Reference |
|---|---|---|---|---|
| AceMod | Agent-based model (ABM) | Investigate the SARS-CoV-2 pandemic properties in Australia | NS | [ |
| CVA | Optimizer algorithm | Imitating the spread of SARS-CoV-2 infection across several countries | Showed more efficiency than VEA, GWO, and PSO in several optimization problems | [ |
| RF, and CCA | ML | Investigating the air pollution factor in SARS-CoV-2 infectivity | High accuracy of SMR (R^2 = 0.95 and RMSE = 28.9) and SPR (R^2 = 0.93 and RMSE = 20.3) values | 10 New |
| XGBoost | ML | Investigating the probability of mortality of an individual SARS-CoV-2 patient | More than 90% Accuracy | [ |
| Survival Cox | DL | Identifying SARS-CoV-2 patients at risk of developing critical illnesses | AUC of 91.1%, and C-index of 89.4% | [ |
| SVM, and DT | ML | Recognizing SARS-CoV-2 patients with the potential to develop more critical illnesses | Accuracy of 70–80% | [ |
| STN | DL | Predicting the severity of the SARS-CoV-2 infection by LUS images | F1-score of 65.1 for full model, and a pixel-wise accuracy of 96% for the segmentation model | [ |
| Viterbi algorithm, Hidden Markov method, and SVM | ML | Evaluating the pathological severity of the infection by LUS images | Accuracy in pleura detection for linear and convex probes was 94% and 84%, respectively | [ |
| MLP, and LSTM | ML | Employing CT images data to forecast malignant progression in infectious patients | AUC of 95.4% | [ |
Repurposed drugs which their efficiency in inhibition of SARS-CoV-2 infection is predicted by artificial intelligence.
| Name | Target | Prediction method | In vitro approved effect | Original clinical uses | References |
|---|---|---|---|---|---|
| Atazanavir | 3C-like protease | DL (MT-DTI), ML (NLP, and NB), and AutoDock Vina | - | HIV | [ |
| Astemizole | VCP, RHOA, TK2 | ML (SVM, and RBF) | - | Antihistamine | [ |
| Baricitinib | AAK1 protein Janus kinase (JAK) | BenevolentAI | - | Rheumatoid arthritis | [ |
| Bazedoxifene | VCP, RHOA, ABCC1 | ML (SVM, and RBF) | - | Postmenopausal osteoporosis | [ |
| Bedaquiline | 3C-like protease | DL (DNN), in-vitro antiviral assays | + | Tuberculosis | [ |
| Brequinar | 3C-like protease | DL (DNN), in-vitro antiviral assays | + | Immunosuppressant | [ |
| Celecoxib | 3C-like protease | DL (DNN), in-vitro antiviral assays | + | Anti-inflammatory | [ |
| Clofazimine | Antiviral activities | DL (DNN), in-vitro antiviral assays | + | Leprosy | [ |
| Conivaptan | Nucleocapsid protein, 3C-like protease | Homology modeling, molecular docking, supervised ML (NN, and NB), DL (DNN), and in-vitro antiviral assays | + | Hyponatremia | [ |
| Dabrafenib | BRD4, PSEN2, IDE | ML (SVM, and RBF) | - | Anti-Cancer | [ |
| Darolutamide | TK2, TBK1, VCP | ML (SVM, and RBF) | - | Prostate cancer | [ |
| Efavirenz | 3C-like protease | DL (MT-DTI), ML (NLP), and AutoDock Vina | - | HIV | [ |
| Entrectinib | IDE, MARK2, VCP | ML (SVM, and RBF) | - | Anti-Cancer | [ |
| Etoricoxib | BRD4, PRKACA, DCTPP1 | ML (SVM, and RBF) | - | Rheumatoid arthritis | [ |
| Fedratinib | Janus kinase (JAK) | BenevolentAI | - | Myeloproliferative diseases | [ |
| Ganciclovir | 3C-like protease, RNA-dependent RNA polymerase | Homology modeling, DL (DFCNN, and MT-DTI), and AutoDock Vina | - | Cytomegalovirus (CMV) infections | [ |
| Gemcitabine | Antiviral activities | DL (DNN), in-vitro antiviral assays | + | Anti-cancer | [ |
| Grazoprevir | Spike protein | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | Hepatitis C | [ |
| Ibrutinib | BRD4, IDE, TK2 | ML (SVM, and RBF) | - | B cell cancer | [ |
| Lapatinib | PSEN2, IDE, BRD4 | ML (SVM, and RBF) | - | Breast cancer | [ |
| Lasofoxifene | VCP, RHOA, ABHD12 | ML (SVM, and RBF) | - | Osteoporosis | [ |
| Lestaurtinib | BRD2, TBK1, MARK2 | ML (SVM, and RBF) | - | Anti-Cancer | [ |
| Lifitegrast | ITGB1, BRD4, PTGES2 | ML (SVM, and RBF) | - | Dry eye | [ |
| Lopinavir/Ritonavir | RNA Helicase | IDentif.AI, DL (MT-DTI), ML (NLP, and NB), and AutoDock Vina | - | HIV | [ |
| Lumacaftor | IMPDH2, EIF4H, BRD2 | ML (SVM, and RBF) | - | Cystic fibrosis | [ |
| Midostaurin | TBK1, BRD2, MARK3 | ML (SVM, and RBF) | - | Acute myeloid leukemia (AML) | [ |
| Paritaprevir | Spike protein, 2′-o-ribose methyltransferase | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | Hepatitis C | [ |
| Remdesivir | 3C-like protease | IDentif.AI, DL (MT-DTI), ML (NLP), and AutoDock Vina | - | Antiviral | [ |
| Ribociclib | PRKACA, ABCC1, HDAC2 | ML (SVM, and RBF) | - | Breast cancer | [ |
| Ritonavir | 3C-like protease | IDentif.AI, DL (MT-DTI), ML (NLP, and NB), and AutoDock Vina | - | HIV | [ |
| Ruxolitinib | Janus kinase (JAK) | BenevolentAI | - | Myelofibrosis | [ |
| Simeprevir | Spike protein | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | Hepatitis C | [ |
| Talazoparib | CSNK2A2, BRD4, BRD2 | ML (SVM, and RBF) | - | Breast cancer | [ |
| Telmisartan | NSD2, PRKACA, PTGES2 | ML (SVM, and RBF) | - | Hypertension | [ |
| Tolcapone | 3C-like protease | DL (DNN), in-vitro antiviral assays | + | Parkinson's disease | [ |
| Triazolam | CSNK2b, RIPK1, DCTPP1 | ML (SVM, and RBF) | - | Insomnia | [ |
| Velpatasvir | Spike protein | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | Hepatitis C | [ |
| Vidarabine | 3C-like protease | Homology modeling and DL (DFCNN) | - | Antiviral | [ |
| Vismodegib | 3C-like protease | DL (DNN), in-vitro antiviral assays | + | Basal-cell carcinoma (BCC) | [ |
Fig. 1AI-predicted FDA-approved drugs that have exhibited effectiveness in anti-SARS-CoV-2 assays.
AI-predicted compounds with potential in the treatment of the SARS-CoV-2 infection. Not Available.
| Name | Target | Prediction method | In vitro approved effect | Original clinical uses | References |
|---|---|---|---|---|---|
| Amyrin | Nucleocapsid protein, Spike protein, 2′-o-ribose methyltransferase | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | NA | [ |
| Chlorobutanol | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| D-Mannitol | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| D-Sorbitol | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| Ebselen | 3C-like protease | "In-silico screening, FRET assay, in-vitro antiviral assays | + | NA | [ |
| Ile + Lys + Pro | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| Loniflavone | Spike protein | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | NA | [ |
| Meglumine | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| Palmatine | 3C-like protease | DL(DeepScreening), AutoDock VINA, ADMET analysis, and MM-PBSA | - | NA | [ |
| Sauchinone | 3C-like protease | DL(DeepScreening), AutoDock VINA, ADMET analysis, and MM-PBSA | - | NA | [ |
| Sodium_gluconate | 3C-like protease | Homology modeling and DL (DFCNN) | - | NA | [ |
| ZINC000008635575 | Spike protein, 2′-o-ribose methyltransferase | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | NA | [ |
| ZINC000027215582 | Nucleocapsid protein, Spike protein, 2′-o-ribose methyltransferase | Homology modeling, AutoDock VINA, molecular docking, and supervised ML (NN, and NB) | - | NA | [ |
An outline of the employed novel AI models in the treatment of the SARS-CoV-2 infection.
| Method | Type | Purpose of analysis | Performance | Reference |
|---|---|---|---|---|
| trRosetta | MD | Simulating the 3D structure of ten viral SARS-CoV-2 proteins | Less than 1.5 MolProbity score for the generated models | [ |
| Several methods | ML and DL | Publishing ideal 3D designs of Mpro | 28 ML models were employed to optimize the reward function | [ |
| CNN | DL | Estimating the localization of sub-cellular viral proteins of SARS-CoV-2 | Accuracy of more than 98% | [ |
| AIMDP, and CNN | DL | Predicting the response of SARS-CoV-2 patients to treatment | Achieved more precision, accuracy, and sensitivity than other models such as COVNet and DeConNet | [ |
| Radiomics | ML and DL | Anticipating the patient end-result concerning ICU acceptance | AUC of 75% | [ |
| 3D analysis and 2D slice-level methods | ML and DL | Assess the progress of the infection in each SARS-CoV-2 patients over time | AUC of 99.6%, sensitivity of 98.2%, and specificity of 92.2% | [ |
Fig. 2Prevalent machine learning algorithms in SARS-CoV-2 research.